Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site (RESPECT)

Hematologic Malignancy Clinical Trial

— RESPECT  

Official title:

Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04628234
• Other study ID #: 2020-001
• Secondary ID: 2020-A00439-30
• Status: Completed
• Start date: July 4, 2020
• Est. completion date: January 9, 2021

Study information

• Verified date: January 2021
• Source: Institut de cancérologie Strasbourg Europe
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a non randomized, monocentric, descriptive, transversal and prospective study. The purpose of this study is to assess the compliance with patient expressed choice regarding subsequent care and death -if occured- site (at hospital or at home) after hospitalisation for terminally ill patients with an onco-hematologic solid tumor in palliative care and to identify reasons for potential non-compliance.

Description:

Patients will reply to two questionnaires, at inclusion and two months after inclusion. Primary care physician will also be contacted by phone to reply to two questionnaires, at inclusion and two months after inclusion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: January 9, 2021
• Est. primary completion date: January 9, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must be = 18 years old

• Patients with onco-hematologic solid tumor (locally advanced or metastatic) against which specific and systemic treatments are outdated or have been stopped (symptomatic palliation with radiotherapy is allowed)

• Patients admitted in full hospitalisation

• Patients able to speak, read and understand French

• Patients able to answer the phone

• Signed informed consent from the patient

• Patients must have a social security coverage

Exclusion Criteria:

• Patients < 18 years old or incapable person = 18 years old

• Patients admitted for any surgical intervention

• Patients unable to read French

• Patients whose physical or psychological condition do not allow them to answer orally or in writing

• Patients deprived of liberty

• Patients placed under judicial protection

• Women that are pregnant or breast-feeding

Related Conditions & MeSH terms

• Hematologic Malignancy
• Hematologic Neoplasms
• Tumor, Solid

Locations

Country	Name	City	State
France	Institut de Cancerologie Strasbourg Europe	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
Institut de cancérologie Strasbourg Europe

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients for which their choice of care and death -if occured- site (at hospital or at home) is respected.	Patients will fill out a questionnaire at inclusion and 2 months after inclusion if they are still alive. Death site will be collected from primary care physician if patient died.; The patient expressed choice regarding subsequent care and death site collected in the first questionnaire at inclusion will be compared to the situation at 2 months.	2 months after inclusion
Secondary	Number of new hospitalisations occuring after inclusion, if any.		2 months after inclusion
Secondary	Duration of new hospitalisations occuring after inclusion, if any.		2 months after inclusion
Secondary	Reasons for new hospitalisations occuring after inclusion, if any.		2 months after inclusion